Pharmacokinetics of danofloxacin after single oral and intravenous administration in non‐laying hens

The current study aimed to explore the pharmacokinetics of danofloxacin in non‐laying hens after a single oral (PO) and intravenous (IV) dose, both at 5 mg/kg body weight (BW). Eighteen 13‐week‐old healthy hens were equally and randomly divided into two groups. After both doses, blood samples (appro...

Full description

Saved in:
Bibliographic Details
Published inJournal of veterinary pharmacology and therapeutics Vol. 46; no. 2; pp. 119 - 124
Main Authors Chen, Jun‐Cheng, Kang, Ji‐Jun, Zhang, Mei, Shao, Hao‐Tian, Song, Zhe‐Wen, Ma, Kai‐Li, Yang, Fang, Yang, Fan
Format Journal Article
LanguageEnglish
Published England 01.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The current study aimed to explore the pharmacokinetics of danofloxacin in non‐laying hens after a single oral (PO) and intravenous (IV) dose, both at 5 mg/kg body weight (BW). Eighteen 13‐week‐old healthy hens were equally and randomly divided into two groups. After both doses, blood samples (approximately 1 ml) were collected at different time points. Danofloxacin concentrations were quantified by a validated high‐performance liquid chromatography (HPLC) method followed by a non‐compartmental analysis using the software of WinNonLin. The elimination half‐lives (t1/2λzs) after PO and IV routes were determined as 8.15 ± 3.37 and 7.69 ± 3.40 h, respectively. After IV administration, danofloxacin had an initial concentration (C0) of 3.62 μg/ml, a volume of distribution at steady state (VSS) of 3579.72 ± 454.29 ml/kg, and a total body clearance (Cl) of 0.49 ml/h/g. After PO administration, the absolute bioavailability and absorption half‐life (t1/2ka) were calculated as 100.99% ± 23.10% and 0.82 ± 0.58 h, respectively. Based on the calculated ratio values of AUC/MIC and Cmax/MIC, an oral dose of 5 mg/kg danofloxacin would be expected to successfully treat hens infected with strains with MIC values ≤0.1 μg/ml.
ISSN:0140-7783
1365-2885
DOI:10.1111/jvp.13098